Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021) - The Lancet Oncology

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Cancers, Free Full-Text

ICU :: Investigative and Clinical Urology

PDF) Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond

How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology

New insights and options into the mechanisms and effects of combined targeted therapy and immunotherapy in prostate cancer: Molecular Therapy - Oncolytics

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Latest from CheckMate 650: Nivolumab plus ipilimumab for the treatment of metastatic castration-resistant prostate cancer - ecancer

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial - ScienceDirect

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies - McGregor - 2021 - Cancer - Wiley Online Library